Liposomal NAD+: The Latest Human Clinical Trial Proves a 1.5× Absorption Breakthrough

The Cellular Energy Revolution

Across the global health landscape, a revolution is taking place, one that goes beyond traditional nutrition and focuses on the cellular foundation of human vitality. Central to this transformation is NAD+ (nicotinamide adenine dinucleotide), a molecule vital for energy metabolism, DNA repair, and longevity.

Still, traditional NAD+ supplements have had a hard time showing clear benefits. Due to its large molecular size and low permeability, NAD+ cannot efficiently pass through biological membranes, resulting in minimal cellular uptake and limited measurable outcomes. This challenge has long been recognized as a major barrier to achieving meaningful efficacy from conventional NAD+ supplementation.

Recent advances in liposome technology have changed this reality. With LipoAvail® liposomal NAD+, scientists have demonstrated a 1.52× increase in bioavailability in a human clinical study, proving that advanced delivery science can finally make NAD+ supplementation effective.

The findings mark a new era in cellular health, where scientific innovation translates into real biological results and measurable liposomal benefits for human vitality.

NAD+: The Core of Cellular Vitality

NAD+ is a coenzyme that is present in all the cells of the body and without which the biochemical processes that keep us alive cannot take place. It is the main agent of mitochondrial function; it is an enzyme that helps in DNA repair, and ultimately, energy is what drives the entire process. However, according to research, the level of NAD+ in the body keeps declining with age, thus causing the metabolism to slow down, the oxidative stress to increase, and the cellular resilience to decrease^[1].

NAD+ or nicotinamide adenine dinucleotide is a coenzyme that is found in every cell of a living organism. It is essentially the origin of life and makes up the biochemical processes that keep the human body going. It is the primary source of energy to the mitochondria, it helps DNA repair, and it is the main mechanism of energy change in the body. But, as per the study, the concentration of NAD+ drops slowly with age, thus causing the metabolism to slow down, oxidative stress to increase, and the ability of the cells to resist to decrease.

This biological limitation has driven a global scientific search for delivery systems capable of protecting NAD+ and ensuring it reaches the cells intact, setting the stage for the next generation of liposomal NAD+ products.

The Challenge: Why Regular NAD+ Fails to Deliver

Despite NAD+ being critical for life, traditional oral supplements have struggled to produce consistent clinical outcomes. The reasons are biochemical:

• Poor oral bioavailability: due to its large molecular size and low membrane permeability, NAD⁺ is poorly absorbed through the intestinal lining, resulting in minimal entry into the bloodstream.
• Large molecular size: NAD+ cannot easily penetrate cell membranes.
• Lack of human data: while the market is flooded with NAD+ and NMN products, very few have published human clinical validation.

Due to the absence of trustworthy evidence, the demand for a delivery system that could shield, carry, and free NAD+ effectively in the body was very obvious.

The Solution: Liposome Technology Unlocks NAD+ Potential

Liposomes are microscopic phospholipid vesicles that mimic human cell membranes. Due to their structural similarity to cell membranes, they can effectively promote the absorption of active ingredients and enhance cellular uptake^[2].

LipoAvail® liposome technology by EffePharm uses this principle to break the absorption barrier of NAD+. In this way, NAD+ is enclosed in a double lipid layer, allowing an efficient uptake from the blood circulation and finally into cells.

Through liposome technology, EffePharm has converted theoretical biochemistry into measurable human outcomes. The result is an NAD+ supplement that performs efficiently in the body, transforming the field of cellular health supplementation^[2].

Clinically Proven: 1.52× Higher Bioavailability in Humans

EffePharm’s recent human clinical trial on LipoAvail® NAD+ is the most convincing evidence of liposomal efficacy that has been put forward so far. The study was performed with a randomized, self-crossover pharmacokinetic design, and the absorption profiles were recorded through 11 blood collection points over 24 hours.

To measure the uptake of NAD+, three key parameters: Cmax (peak concentration), Tmax (time to peak), and AUC (total exposure), were examined. The findings demonstrated that liposomal NAD+ raised bioavailability by 1.52× (p < 0.05) relative to the standard forms.

Additional animal experiments that accompanied the human studies provided very strong evidence for the same conclusion. These experiments showed that when NAD+ was given in a liposomal form for 14 days, its relative concentration in the liver increased by nine times.

It is the first clinically verified evidence that liposomal NAD+ is capable of breaking the biological barriers that hinder traditional NAD+ supplementation, thereby making the impressive results of lab studies achievable in actual humans.

For the global nutraceutical industry, this trial establishes a new scientific standard, demonstrating that precise formulation and validated delivery mechanisms are key to advancing cellular health.

Broader Benefits of Liposomal NAD+

These investigations have far greater implications than just absorption rates. Elevated intracellular NAD+ levels are associated with a myriad of bodily functions and health advantages, such as:

• Enhanced mitochondrial energy metabolism and endurance.
• Improved cognitive and metabolic support.
• Strengthened DNA repair and anti-aging defense.
• Organ protection for the liver, heart, and brain.

EffePharm’s LipoAvail® NAD+ is a product that goes through manufacturing processes that conform to cGMP, ISO 9001, Halal, Kosher, and HACCP certifications. This guarantees that it is a reliable and consistent product for clinical and consumer usage. What makes it a scientifically backed supplement providing proven liposomal advantages is the mixture of scientific accuracy with tight manufacturing standards.

The Future: From Concept to Clinical Reality

The progression of NAD+ supplementation is moving beyond just theoretical claims to actual solutions backed by data. EffePharm is leading this transition by a continued investment in liposome technology, human trials, and scalable production.

As the market is accepting a new era of scientific transparency, liposomal NAD+ is getting recognized as the new standard for cellular health. Its ability, as demonstrated in humans, to raise NAD+ levels is changing the way supplements are developed, validated, and trusted.

By these innovations, EffePharm is the first to move the “conceptual anti-aging” idea to a clinically verified cellular rejuvenation. The next step in health innovation is not in the form of promises but rather evidence, and that evidence is now very clear that it is liposomal NAD+ that should be chosen.

References：

[1] Covarrubias, A. J., Perrone, R., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119– https://doi.org/10.1038/s41580-020-00313-x

[2] Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975– https://doi.org/10.2147/IJN.S68861